SOURCE: Crucell N.V.

December 17, 2007 02:00 ET

Crucell Announces Research License Agreement with ProFibrix on STAR® Technology

LEIDEN, NETHERLANDS--(Marketwire - December 17, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with ProFibrix BV. The license with The Netherlands based ProFibrix covers the production of specific forms of human fibrinogen, a protein involved in haemostasis (blood clotting) and tissue repair. Financial details of the agreement were not disclosed.

About STAR® Technology

STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® technology and the widely used Chinese Hamster Ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements, that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs. STAR® technology was discovered by Dr. Arie Otte (Nature Biotechnology 2003 May 21, (5)) who founded Chromagenics B.V., a spin-off company of the University of Amsterdam, acquired by Crucell in March 2004.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com

About ProFibrix

ProFibrix B.V. is a Dutch biotechnology company that was founded in January 2004 and is located in the Bioscience Park, Leiden, The Netherlands. The company aims to create, develop and market new and innovative healthcare products, based on the unique properties of human fibrinogen. The lead product of the company is FibrocapsTM, a dry powder fibrin sealant based on plasma derived fibrinogen and thrombin that is currently being developed as a topical haemostat for the treatment of severe bleeding during surgery and after trauma injury. ProFibrix is also developing a recombinant manufacturing platform to produce specific variants of fibrinogen for the development of high-added value haemostasis and tissue repair products. The company has developed an extensive network of academic and industrial collaborations that support the R & D activities.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20- F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS) with reconciliation to the generally accepted accounting principles in the United States (US GAAP).

For further information please contact:


Media:                            Investors/Analysts:
Barbara Mulder                    Oya Yavuz
Director Corporate Communications Director Investor Relations
Tel: +31-(0)71-519 7346           Tel. +31-(0)71-519 7064
press@crucell.com                 ir@crucell.com

PDF file: http://hugin.info/132631/R/1176383/233499.pdf



Copyright © Hugin ASA 2007. All rights reserved.

Contact Information